FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma

FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma The detection of fibroblast growth factor receptor 3 (FGFR3) mutations in noninvasive bladder cancer mostly and a finding of FGFR3 overexpression in many invasive bladder cancers (BC) has created hope that targeted therapy against FGFR3 may have a major role in the treatment of BC. We aimed to evaluate immunohistochemically the expression of FGFR3 in urothelial carcinoma of the urinary bladder and correlate the results with various clinicopathologic variables to show the possible prognostic value of this marker. This study included 100 archived paraffin blocks of variable grades and stages of urothelial carcinoma. All cases were immunohistochemically stained with anti-FGFR3 antibody. FGFR3 immunostaining was detected in 88% (88/100) of urothelial carcinoma cases. A significant correlation was detected between FGFR3 expressions with the grade and depth of tumor invasion as 34% of low-grade cases (P = 0.002) and 26% of pTa-stage tumors (P = 0.02) showed high level of FGFR3 expression. Moreover, FGFR3 was significantly highly expressed in 34% of non-muscle-invasive tumors (P = 0.007), 34% of tumors with papillary growth pattern (P = 0.017), and lower-stage tumors (P = 0.00). In conclusion, high expression of FGFR3 in urothelial carcinomas with statistically significant relationships regarding its expression levels with parameters of favorable prognosis like low grade and pTa stage, presence of papillary architecture, and lower-stage urothelial carcinomas raised the probability that FGFR3 expression may have a role in early development of urothelial neoplasia. Further studies are required to investigate the applicability of FGFR3-targeted agents as an additional treatment regimen in patients with FGFR3 overexpression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Comparative Clinical Pathology Springer Journals

FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma

Loading next page...
Springer London
Copyright © 2017 by Springer-Verlag London Ltd.
Medicine & Public Health; Pathology; Hematology; Oncology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial